Magenta Medical Ltd.
- Industry
- Medical Device
- Founded Year
- 2012
- Headquarters
- 1 Ha'ofeh St, Kadima, Central District, 60920, Israel
- Employee Count
- 84
Key People
- David Israeli - CEO
- Ehud Schwammenthal - Founder, CMO
- Yosi Tuval - Founder
- Gilead Moiseyev - COO
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The founding team has a strong track record in MedTech entrepreneurship.
Founders Prof. Ehud Schwammenthal and Mr. Yosi Tuval previously founded Ventor Technologies, acquired by Medtronic in 2009, demonstrating their ability to develop and commercialize MedTech innovations.
- Clinical Need
-
Aspect: Very Strong
Summary: Addressing a critical need in acute heart failure management.
Magenta's Elevate device provides mechanical circulatory support for patients undergoing high-risk percutaneous coronary interventions and those with cardiogenic shock, conditions with significant morbidity and mortality.
- Competition
-
Aspect: Somewhat crowded
Summary: The market has existing players but room for innovation.
The mechanical circulatory support market includes established devices like Impella by Abiomed, but Magenta's focus on miniaturization and percutaneous delivery offers a competitive edge.
- Technical Challenge
-
Aspect: Complex
Summary: Developing miniaturized, high-flow heart pumps is technically demanding.
The engineering required to create a small yet powerful percutaneous left ventricular assist device involves overcoming significant technical hurdles related to materials, mechanics, and biocompatibility.
- Patent
-
Aspect: Strong
Summary: The company holds robust intellectual property in miniaturized blood pump technology.
Magenta's proprietary technology includes self-expanding impellers and pump heads, which are critical to the functionality and uniqueness of their devices.
- Financing
-
Aspect: Well-funded
Summary: The company has secured substantial funding from reputable investors.
Magenta Medical has raised significant capital, including a $105 million round led by Novo Holdings in 2024, indicating strong investor confidence and financial stability.
- Regulatory
-
Aspect: Pivotal Trial
Summary: The device is progressing through advanced clinical trials.
Magenta's Elevate system has been granted Breakthrough Device Designation by the FDA and is preparing for pivotal studies, indicating a clear regulatory pathway.
Opportunity Rollup
- Odds of Success
- 3.45
- Peak Market Share
- 4.3
- Segment CAGR
- 5.8%
- Market Segment
- Cardiac Assist Devices
- Market Sub Segment
- Percutaneous Left Ventricular Assist Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.22 |
| 2 | 0.64 |
| 3 | 1.50 |
| 4 | 3.01 |
| 5 | 4.30 |
Key Takeaway
Magenta Medical's innovative approach to mechanical circulatory support positions it well in a growing market, but success hinges on overcoming technical challenges and navigating a competitive landscape.